« Home | Anthrax vaccinations expected to resume in late Ja... » | 'They don't stand by me now' » | Mandatory anthrax vaccinations raise concerns » | Ross: Arsenal Ideal Site For Vaccine Production - ... » | Q and A - Mandatory AVIP Resumption » | World Death Toll Of a Flu Pandemic Would Be 62 Mil... » | Which is More Dangerous to Your Health-the Flu or ... » | Quest for Anthrax Vaccine Lengthens - Questions Su... » | What demise of anthrax vaccine contract means for ... » | Drugmakers to receive tax dollars to boost fight a... »

Emergent Biosolutions initiated with "outperform" - update

Cowen & Co

NEW YORK, January 4 (newratings.com) - Analysts at Cowen & Co initiate coverage of Emergent Biosolutions (ticker: EBS) with an "outperform" rating.

In a research note published yesterday, the analysts mention that following the termination of VaxGen’s contract for a recombinant anthrax vaccine, Emergent Biosolutions is expected to be given a considerable portion of the $877 million contract by HHS within the forthcoming six-to-twelve months. Emergent Biosolutions is developing other biodefense and commercial vaccine products targeting anthrax and botulinum, the analysts say. There is significant upside to Emergent Biosolutions’ share price over the next 12 months due to newsflow related to the company’s biodefense products, Cowen & Co adds.